Srdan Verstovsek
Overview
Explore the profile of Srdan Verstovsek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
641
Citations
19152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masarova L, Verstovsek S, Liu T, Rao S, Sajeev G, Fillbrunn M, et al.
Future Oncol
. 2024 Jul;
20(30):2259-2270.
PMID: 39072442
To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Cost and time burden were calculated based on the transfusion...
2.
Kadia T, Huang M, Pemmaraju N, Abbas H, Ly C, Masarova L, et al.
NEJM Evid
. 2024 May;
3(6):EVIDoa2300362.
PMID: 38804782
Background: An inflammatory bone marrow microenvironment contributes to acquired bone marrow failure syndromes. CK0801, an allogeneic T regulatory (Treg) cell therapy product, can potentially interrupt this continuous loop of inflammation...
3.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, et al.
Am J Hematol
. 2024 Apr;
99(7):1434-1436.
PMID: 38613831
No abstract available.
4.
Bose P, Masarova L, Pemmaraju N, Bledsoe S, Daver N, Jabbour E, et al.
Haematologica
. 2024 Apr;
109(8):2660-2664.
PMID: 38572554
No abstract available.
5.
Verstovsek S, Mesa R, Talpaz M, Kiladjian J, Harrison C, Oh S, et al.
Haematologica
. 2024 Apr;
109(4):3010.
PMID: 38562076
No abstract available.
6.
Oh S, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian J, et al.
EJHaem
. 2024 Feb;
5(1):105-116.
PMID: 38406514
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present...
7.
Kremyanskaya M, Kuykendall A, Pemmaraju N, Ritchie E, Gotlib J, Gerds A, et al.
N Engl J Med
. 2024 Feb;
390(8):723-735.
PMID: 38381675
Background: Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis....
8.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer J, et al.
Ther Adv Hematol
. 2024 Feb;
15:20406207241229588.
PMID: 38380373
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited...
9.
Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva A, Ivan C, Gulei D, et al.
JCI Insight
. 2024 Feb;
9(3).
PMID: 38329131
No abstract available.
10.
Hudgens S, Verstovsek S, Floden L, Harrison C, Palmer J, Gupta V, et al.
Value Health
. 2024 Feb;
27(5):607-613.
PMID: 38311180
Objectives: Patients with myelofibrosis develop symptoms due to bone marrow fibrosis, systemic inflammation, and/or organomegaly. Alleviating symptoms improves overall quality of life. Clinical trials have historically defined symptom response as...